Colonial Trust Advisors’s GSK GSK Stock Holding History

Colonial Trust Advisors’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$50.8K	Sell	1,055 -100	-9%	-$5.11K	﹤0.01%	367
2026 Q2	$60.5K	Hold	1,155	–	–	﹤0.01%	350
2026 Q1	$63.7K	Buy	1,155 +100	+9%	+$5.42K	0.01%	320
2025 Q4	$51.7K	Hold	1,055	–	–	﹤0.01%	341
2025 Q3	$45.5K	Hold	1,055	–	–	﹤0.01%	347
2025 Q2	$40.5K	Sell	1,055 -4,060	-79%	-$155K	﹤0.01%	369
2025 Q1	$198K	Buy	5,115 +3,868	+310%	+$142K	0.02%	203
2024 Q4	$42.2K	Hold	1,247	–	–	﹤0.01%	335
2024 Q3	$51K	Hold	1,247	–	–	﹤0.01%	332
2024 Q2	$48K	Hold	1,247	–	–	﹤0.01%	327
2024 Q1	$53.5K	Hold	1,247	–	–	0.01%	317
2023 Q4	$46.2K	Hold	1,247	–	–	﹤0.01%	325
2023 Q3	$45.2K	Hold	1,247	–	–	0.01%	337
2023 Q2	$44.4K	Hold	1,247	–	–	﹤0.01%	348
2023 Q1	$44.4K	Hold	1,247	–	–	0.01%	344
2022 Q4	$43.8K	Buy	+1,247	New	+$41.5K	0.01%	346

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return

JTC Employer Solutions Trustee St Helier, Jersey $1.16B AUM 24.39% 1-Year Est. Return

Mondrian Investment Partners London, United Kingdom $5.39B AUM 14.53% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return

Equity Investment Corp Atlanta, Georgia $5.3B AUM 8.71% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $57.2B AUM 42.49% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $313B AUM 26.62% 1-Year Est. Return

Colonial Trust Advisors's GSK Position: Q3 2026 in Review

Colonial Trust Advisors reduced its GSK (GSK) stake by 8.7% in Q3 2026, selling an estimated $5.11K and leaving 1,055 shares worth $50.8K. The position accounts for ﹤0.01% of the portfolio, ranked #367.

Colonial Trust Advisors first reported a position in GSK in Q4 2022 and has held it in 16 quarters since. The position peaked at $198K in Q1 2025. 654 funds tracked by Wall St. Rank hold GSK as of Q3 2026.

Colonial Trust Advisors held 1,055 shares of GSK worth $50.8K as of Q3 2026.
Colonial Trust Advisors sold 100 GSK shares in Q3 2026, an estimated $5.11K.
GSK made up ﹤0.01% of Colonial Trust Advisors's portfolio in Q3 2026, its #367 holding.
Colonial Trust Advisors first reported a position in GSK in Q4 2022 and has held it in 16 quarters since.
Colonial Trust Advisors's GSK position peaked at $198K in Q1 2025.
654 funds tracked by Wall St. Rank held GSK as of Q3 2026.

Based on Colonial Trust Advisors's 13F filing for Q3 2026, filed 10 Nov 2026.